We are live on
!
Find out more
TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
1-Year Est. Return
58.09%
This Fund
S&P 500
This Quarter
Est. Return
+12.23%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$299M
AUM Growth
+$88.5M
(+42%)
Cap. Flow
+$67.2M
Cap. Flow
% of AUM
22.49%
Top 10 Holdings %
Top 10 Hldgs %
67.92%
Holding
32
New
5
Increased
19
Reduced
3
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
OPTN
OptiNose
OPTN
|
+$12.2M |
| 2 |
Medtronic
MDT
|
+$11.2M |
| 3 |
Labcorp
LH
|
+$9.84M |
| 4 |
Rigel Pharmaceuticals
RIGL
|
+$9.34M |
| 5 |
Lantheus
LNTH
|
+$8.76M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
QuidelOrtho
QDEL
|
+$8.55M |
| 2 |
Alkermes
ALKS
|
+$6.38M |
| 3 |
Steris
STE
|
+$4.2M |
| 4 |
CERN
Cerner Corp
CERN
|
+$2.61M |
| 5 |
VSI
Vitamin Shoppe Inc.
VSI
|
+$1.06M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.45% |
| 2 | Industrials | 5.46% |
| 3 | Consumer Discretionary | 4.47% |
| 4 | Miscellaneous | 0.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
NovoCure
NVCR
$2.09B
| $34.4M | 11.53% |
1,100,000
-15,000
| -1% | -$417K |
|
|
2
Medtronic
MDT
$120B
| $27.7M | 9.29% |
324,000
+134,000
| +71% | +$11.2M |
|
|
NUVA
3
DELISTED
NuVasive, Inc.
NUVA
| $26.1M | 8.72% |
500,000
+140,000
| +39% | +$7.33M |
|
|
MDRX
4
DELISTED
Veradigm Inc. Common Stock
MDRX
| $19.2M | 6.43% |
1,600,000
+125,000
| +8% | +$1.54M |
|
|
5
Labcorp
LH
$26.5B
| $18.5M | 6.19% |
119,892
+65,184
| +119% | +$9.84M |
|
|
OPTN
6
DELISTED
OptiNose
OPTN
| $17.5M | 5.85% |
41,667
+36,179
| +659% | +$12.2M |
|
|
SRCL
7
DELISTED
Stericycle Inc
SRCL
| $16.3M | 5.46% |
250,000
+50,000
| +25% | +$3.11M |
|
8
Bio-Rad Laboratories Class A
BIO
$10.3B
| $15.9M | 5.31% |
55,000
+17,100
| +45% | +$4.72M |
|
9
Gilead Sciences
GILD
$187B
| $14.2M | 4.74% |
200,000
+35,000
| +21% | +$2.47M |
|
|
NXTM
10
DELISTED
NxStage Medical Inc.
NXTM
| $13.1M | 4.39% |
470,537
+102,277
| +28% | +$2.74M |
|
11
Dentsply Sirona
XRAY
$2.27B
| $12M | 4.03% |
275,000
+40,000
| +17% | +$1.88M |
|
|
12
Lantheus
LNTH
$6.59B
| $11.4M | 3.82% |
784,619
+569,061
| +264% | +$8.76M |
|
|
CORI
13
DELISTED
Corium International, Inc.
CORI
| $10.9M | 3.66% |
1,364,279
+259,279
| +23% | +$2.45M |
|
|
CORV
14
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
| $7.56M | 2.53% |
2,000,000
+125,000
| +7% | +$326K |
|
|
15
Rigel Pharmaceuticals
RIGL
$909M
| $7.43M | 2.49% |
+262,500
| New | +$9.34M |
|
16
AtriCure
ATRC
$2.62B
| $7.03M | 2.35% |
260,000
+59,000
| +29% | +$1.39M |
|
|
HOLX
17
DELISTED
Hologic
HOLX
| $6.96M | 2.33% |
175,000
+100,000
| +133% | +$3.85M |
|
18
Service Corp International
SCI
$11.2B
| $6.93M | 2.32% |
193,526
+78,526
| +68% | +$2.91M |
|
|
VSI
19
DELISTED
Vitamin Shoppe Inc.
VSI
| $6.43M | 2.15% |
925,000
-194,559
| -17% | -$1.06M |
|
20
Pacira BioSciences
PCRX
$1.05B
| $6.09M | 2.04% |
190,000
+71,298
| +60% | +$2.46M |
|
|
ISEE
21
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $2.52M | 0.85% |
925,000
+76,160
| +9% | +$210K |
|
|
SIEN
22
DELISTED
Sientra, Inc.
SIEN
| $2.44M | 0.82% |
+12,500
| New | +$1.98M |
|
|
LMNX
23
DELISTED
Luminex Corp
LMNX
| $2.33M | 0.78% |
79,089
-15,668
| -17% | -$402K |
|
|
HIND
24
Vyome Holdings
HIND
$15.6M
| – | – |
0
| – | – |
|
|
STRM
25
DELISTED
Streamline Health Solutions
STRM
| $1.65M | 0.55% |
78,153
+5,039
| +7% | +$115K |
|
Similar funds
SCM
LBC
ICM
LCMP
GIP
STC
GC
DU
Tamarack Advisers's Q2 2018 Portfolio in Review
As of Q2 2018, Tamarack Advisers held 32 positions worth $299M, up 42% from $210M the previous quarter. Its ten largest holdings account for 68% of the portfolio.
Tamarack Advisers deployed $67.2M of net new capital in Q2 2018, opening 5 new positions and adding to 19 existing holdings. Its largest new stake was Rigel Pharmaceuticals: 262,500 shares worth $7.43M.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 90% a quarter earlier, followed by Industrials and Consumer Discretionary.
On the sell side, the largest reduction was Vitamin Shoppe Inc., an estimated $1.06M trimmed.
- Tamarack Advisers's largest Q2 2018 buy was Rigel Pharmaceuticals: 262,500 shares worth $7.43M.
- Tamarack Advisers added most to OptiNose in Q2 2018, an estimated $12.2M increase.
- Tamarack Advisers's biggest Q2 2018 reduction was Vitamin Shoppe Inc., cutting an estimated $1.06M.
- Tamarack Advisers fully exited QuidelOrtho in Q2 2018, selling an estimated $8.55M.
- Tamarack Advisers's ten largest holdings make up 68% of its $299M portfolio in Q2 2018.
- Tamarack Advisers opened 5 new positions and closed 4 in Q2 2018.
- Tamarack Advisers's portfolio value rose 42% quarter-over-quarter to $299M.
Based on Tamarack Advisers's 13F filing for Q2 2018, filed 14 Aug 2018.